businesspress24.com - Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance a
 

Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance and Corporate Update, and Host Conference Call

ID: 1410452

(firmenpresse) - MENLO PARK, CA -- (Marketwired) -- 01/21/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2015 financial results and provide 2016 revenue guidance and a corporate update on January 28, 2016. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).



To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode will be 4156 8920.

A replay will be available through February 11, 2016 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode will be 4156 8920.



Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym, a first generation cortisol modulator, is the company''s first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of triple-negative breast cancer and has a portfolio of other proprietary selective GR antagonists that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its portfolio of selective cortisol modulators.



CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Hemostemix Company Information Now Available Through S&P Capital IQ Corporation Records Program
Sernova Announces Agreement With CCRM to Produce Specialized Cells for the Treatment of Diabetes
Bereitgestellt von Benutzer: Marketwired
Datum: 21.01.2016 - 15:05 Uhr
Sprache: Deutsch
News-ID 1410452
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

MENLO PARK, CA


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 273 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance and Corporate Update, and Host Conference Call
"
steht unter der journalistisch-redaktionellen Verantwortung von

Corcept Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Corcept Therapeutics



 

Who is online

All members: 10 591
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 157


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.